Rudolph Navari to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Rudolph Navari has written about Dose-Response Relationship, Drug.
Connection Strength
0.303
-
The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf. 2016; 15(3):343-56.
Score: 0.102
-
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015; 9:155-61.
Score: 0.094
-
Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003 Sep; 37(9):1276-86.
Score: 0.043
-
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017 01; 25(1):303-308.
Score: 0.027
-
The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice. Cancer Lett. 2004 Jun 25; 209(2):165-9.
Score: 0.011
-
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004; 22(3):383-8.
Score: 0.011
-
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998 Apr; 16(4):1568-73.
Score: 0.007
-
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Cancer. 1996 Aug 15; 78(4):789-93.
Score: 0.007